FDA staffers sue agency over email surveillance


Six of the so-called "FDA 9" whistleblowers are suing the federal watchdog agency, alleging that the government violated their constitutional rights with surveillance of their private email accounts.

The staffers allege that the FDA spied on the private email accounts they accessed using their government-issued computers, after they warned Congress and the president that unsafe medical devices were being allowed onto the U.S. market.

The lawsuit, filed in the U.S. District Court for the District of Columbia, levels 12 counts against the agency, its chief Dr. Margaret Hamburg, medical device chief Dr. Jeffrey Shuren, the Dept. of Health & Human Services and its head, Kathleen Sebelius, and other government officials. It accuses them of enacting the secret surveillance after learning of a letter the staffers sent to then-President-elect Barack Obama’s transition team Jan. 7, 2009, and of using the information gleaned from the tapped email accounts to harass and, in some cases, fire the whistleblowers.

After learning of the letter, the FDA set up a secret file on its database labelled "FDA 9" to collect the surveillance data. The agency took screenshots of the staffers’ computers as they accessed their private Gmail accounts, according to the lawsuit. Although the government has the right to surveil any activity on the computers it issues, it’s unclear whether it’s legal to secretly gain access to private email accounts used on government-issued devices.

The staffers later wrote an open letter to Obama asking him to hold former and current officials accountable for their alleged wrongdoing. The Jan. 7 letter to John Podesta, the transition team leader, warned that potentially unsafe radiological devices were being allowed to hit the market.

"For example, in the January 7, 2009 letter to Mr. Podesta, the FDA scientists noted that in the past, computer-aided detection devices (‘CAD’) to be used with breast mammograms were not safe or effective, but the FDA approved the devices anyway in a flawed process that ignored the science. This has led to significant harm to large numbers of women and significant unnecessary costs to the public," according to the lawsuit. "After the defendants learned about the Jan. 7, 2009, letter to Mr. Podesta, FDA officials began to secretly refer to the signatories of the letter from the FDA scientists and including [the plaintiffs] as the ‘FDA Nine’ or ‘FDA 9.’"

The FDA staffers also communicated with aides of Sen. Charles Grassley (R-Iowa), who then warned the FDA not to retaliate against the whistleblowers.

But, "despite Senator Grassley’s warnings," the agency "commenced a covert and secret search and seizure operation on the ‘FDA Nine’ in retaliation for their protected speech, which included, but was not limited to, the interception of private communications sent by or on behalf of plaintiffs to congressional representatives," according to the lawsuit.

"The information secretly obtained by defendants included plaintiffs’ legally protected documents and information that was stored by plaintiffs in folders labeled ‘For Congress’ and other folders that clearly indicated the intent of plaintiffs to raise issues of public concern with appropriate authorities," according to the complaint.

"Defendants have taken and converted private emails without due process or just compensation in violation of the 5th Amendment of the United States Constitution. Defendants have initiated searches and seizures in violation of the 1st and 4th Amendments. Defendants have conducted searches and seizures of a scope that violates the 1st and 4th Amendments. Defendants have violated the 1st Amendment by chilling free speech with searches and seizures. Defendants have violated the 1st Amendment by chilling Plaintiffs’ and the public’s right to associate with whistleblowers. Defendants have violated plaintiffs’ right to representation. Defendants have chilled plaintiffs’ protected 1st Amendment right to free speech."

Documents obtained by the Washington Post show that the FDA twice asked the HHS inspector general’s office to investigate the whistleblowers, accusing them of illegally releasing confidential business information about the devices they believed were unsafe.

"We have obtained new information confirming the existence of information disclosures that undermine the integrity and mission of the FDA and, we believe, may be prohibited by law," Shuren wrote, according to the documents.

But both times the IG’s office declined to intervene.

"Who would have thought that they would have the nerve to be monitoring my communications to Congress?" Robert Smith, one of the plaintiffs in the suit, told the Post. "How dare they?"

Michael Sussmann, a former federal prosecutor who is now a partner at the Perkins Coie law firm, told the newspaper that the FDA has the latitude to conduct extensive monitoring.

"Anything on this agency’s network is fair game by use of this banner, as long as they’re lawfully targeting their employee," Sussman said.

Federal investigators later cleared the FDA managers of criminal acts against the whistleblowers.

“We do have a zero tolerance policy for retaliation,” Shuren said at the time.

"The FDA has a huge responsibility to protect public health and safety," Grassley said in a statement to the Post. "It’s hard to see how managers apparently thought it was a good use of time to shadow agency scientists and monitor their e-mail accounts for legally protected communications with Congress."

RSS From Medical Design & Outsourcing

  • GlobTek presents its latest level VI AC/DC adapter and connverter
    T-43086-WWVV-X.X-Q Model is an addition to GlobTek’s Level VI compliant GT-43086 family and represents GlobTek’s 6 Watt wall plug-in series of AC/DC adapters (power supplies and chargers) with International Interchangeable blades. GlobTek’s changeable input blade system with individual field replaceable input plugs, including: North America and Japan NEMA 1-15P, Australian, UK BS 1363, European CEE […]
  • Sanmina’s familiarity with FDA gets skin treatment product to market fast
    The medical market for cosmetic devices is booming. However, quickly launching new products to meet demand is becoming more challenging because device manufactures face increased regulatory scrutiny. To help meet regulatory requirements, aesthetic and other medical-device OEMs are partnering with electronics manufacturing services (EMS) companies that also offer expertise with the FDA filings necessary to […]
  • Fluid connectors and quick disconnects for IVD equipment from CPC
    Colder Products Company (CPC) offers thousands of tubing connectors, quick disconnects and fittings for smart fluid handling in IVD and analytical equipment. Non-spill connectors speed testing throughput by eliminating drips, preventing air inclusion and increasing operator safety. Panel mount connectors can be added to existing equipment or bottle caps to provide secure, leak-free connections. Puncture […]
  • 310 Watt desktop medical power supply meets efficiency level VI requirements
    Power Partners releases a new 310 Watt medical grade desktop power supply from their PEAMD Series of AC and DC adapters. The 310 Watt unit is packed for ideal performance inside a compact case measuring 7.8 x 4 x 2 in. with a weight of only 3 lbs. The PEAMD310 Series is approved to the latest […]
  • Saelig introduces Multiple Instrument System MIS4 universal test system
    Saelig Company has introduced the ABI Electronics’ Multiple Instrument Station MIS4, an all-in-one testing tool that provides all commonly required test instruments in one compact programmable hardware module, mounted in a compact case or installed in a PC-drive bay. Controlled by ABI’s sophisticated SYSTEM 8 Ultimate PC software with a simple yet programmable operator interface, […]
  • AssurX announces document management software update for small to mid-size companies in FDA regulated industries
    AssurX, an enterprise quality management, risk and regulatory compliance solution provider, announces the release of the latest update to their AssurX document management software. The document management solution provides a cost-effective solution for small to medium sized companies faced with streamlined operations and is fully compliant for FDA regulated industries. Ideal solution for small to […]
  • Saelig presents new Amplicon Impact-R 1100F series computer
    Saelig Company announces the Amplicon Impact-R 1100F series, a fanless system powered by the Intel ATOM D2550 processor. Configured with a high performance 2.5 in. MLC Solid State Drive (SSD), the Impact-R 1100F series is a silent controller system. With options for multiple serial communication ports, the Impact-R 1100F can offer up seven DB9 connections […]
  • Gerresheimer to acquire Centor
    Gerresheimer AG, a partner to the global pharmacy and healthcare industry, will further extend its pharmaceutical packaging business with the acquisition of Centor. Gerresheimer has reached an agreement with Nemera Development S.A. to acquire 100% of the share capital of Centor US Holding. “Centor is the highly profitable market leader for plastic vials and closures in […]
  • Methods Machine Tools presents the new Nakamura-Tome NTRX-300
    Methods Machine Tools, a developer of precision machine tools and automation, has introduced the new Nakamura-Tome NTRX-300, a multitasking turning center featuring complete parts machining in one operation, with a built-in load and unload automation system and advanced operator recognition management software. The NTRX-300 features true opposing twin spindles: an 8 in. A2-6 25 HP or […]
  • MSC Apex Diamond Python and Smart Midsurface speeds modeling to validation
    MSC Software announced a new release of MSC Apex, the company’s award-winning next generation Computer Aided Engineering (CAE) platform. The MSC Apex Diamond Python release introduces: · The fourth release of MSC Apex Modeler is a CAE Specific direct modeling and meshing solution that streamlines CAD clean-up, simplification and meshing workflow. New in this release is […]
  • Quality Metrics: FDA’s plan for a key set of measurements to help ensure manufacturers are producing quality medications
    Editor’s Note: This article is written by Ashley Boam and Mary Malarkey from the “FDA Voice” blog. Boam is an FDA’s acting Director of the Office of Policy for Pharmaceutical Quality, the Office of Pharmaceutical Quality and the Center for Drug Evaluation and Research. Malarkey is an FDA’s Director if the Office of Compliance and Biologics Quality […]

Leave a Reply